Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Comment by Riverfolkon Dec 06, 2021 12:20pm
98 Views
Post# 34202506

RE:RE:Bring in the cavalry

RE:RE:Bring in the cavalryOne of the main reasons that clinical trials take a tremendous amount of time (3.5 years) is that the quality of drug is increased as the drug moves from Phase I-Phase II-Phase III (10.5 years). This process can take up to 9 months in preparation for the next trial. Often retail does not understand this as the process is not common as with 85% phase II failure rate. Comparing the normal process of issuing phase II results and then preparing for a phase III trial while raising funds from the market... BLU , SAVA, TRIL. ARCH Management looks like they were being proactive, as stated in the recent news release.

The Company’s responsibilities during the trial include supplying LSALT drug vials to support the trial until completion. Arch completed the manufacturing of a new supply of vials during the summer and autumn of this year and has enough drug supply on hand for the 320 patients scheduled to be dosed in the CATCO trial.
 

So now the company has the drug (Metablok/LSALT Peptide) in hand and the Government is funding the trial. This opportunity is extremely rare in this sector and the street doesnt seem to understand it yet. Statistically we now have a 52.8% chance of bringing Metablok to market.

 

<< Previous
Bullboard Posts
Next >>